基于药物相互作用软件评价降糖药物的相互作用

摘要

目的 评价并分析不同降糖药物的药物相互作用(DDI).方法 将目前临床上常用的降糖药物(包括胰岛素和27种非胰岛素制剂)使用DDI数据库Lexi-InteractionTM分析评价其DDI并进行归纳和排序.结果 28种药物共涉及DDI数量882种,其中C级最多(69.8%),C、D、X级占总数的91.2%,其中X级为28种.平均每种药物DDI数量最多的为磺脲类药物,其次为二甲双胍,最少的为α-糖苷酶抑制剂.结论 对于合并用药较多、老年患者及肝肾功能不全者应优先选用DDI数量较少的降糖药物,如α-糖苷酶抑制剂、胰高血糖素样肽-1(GLP-1)类似物、钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)等.%Objective To evaluate and analyze the drug-drug interactions(DDI)of different antidiabetic drugs.Methods DDI database Lexi-InteractionTMwas used to evaluate DDI for 28 commonly used antidiabetic medications(including insulin and 27 non-insulin preparations).Results 882 DDIs were identified for 28 drugs.Category C was the top rated DDI(69.8%). Category C,D,X were accounted for 91.2% of the total DDI.28 medication combinations belonged to category X,which should be avoided to use together.Sulfonylureas had the most DDI,followed by metformin.Alpha-glucosidase inhibitors had least DDI.Conclusion Hypoglycemic drugs with less DDI,such as α-glycosidase inhibitors,glucagon-likepeptide1(GLP-1)an-alogs and sodium-dependent glucose transporters 2 inhibitor(SGLT2i)should be considered with high priority for patients tak-ing multiple antidiabetic medications,elderly patients and patients with liver-kidney dysfunction.